NCT04072731

Brief Summary

In this study, the investigators detected the expression of SREBP1 in thyroid cancer tissues, explored the biological functions of SREBP1 in thyroid cancer cells.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
140

participants targeted

Target at P50-P75 for all trials

Timeline
Completed

Started Jan 2016

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 16, 2016

Completed
1.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

July 30, 2017

Completed
5 months until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2018

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

January 16, 2018

Completed
1.6 years until next milestone

First Posted

Study publicly available on registry

August 28, 2019

Completed
Last Updated

August 28, 2019

Status Verified

August 1, 2019

Enrollment Period

1.5 years

First QC Date

January 16, 2018

Last Update Submit

August 27, 2019

Conditions

Thyroid Cancer

Keywords

thyroid cancerSREBP1

Outcome Measures

Primary Outcomes (1)

  • progression-free survival

    disease recurrent of progression

    average 5 years

Secondary Outcomes (1)

  • theraputic efficacy

    average 18 months

Study Arms (2)

thyroid cancer

the thyroid cancer was determined by the the Pathology Department based on the pathological evidence.

Other: pathologic

the adjacent thyroid tissues

the adjacent thyroid tissues was collected from the tissue that 3 centimeters from the thyroid cancer.

Other: pathologic

Interventions

pathologicOTHER

All the enrolled patients were treated with whole resection and diagnosed by the Pathology Department based on the pathological evidence.

Also known as: radioiodine
the adjacent thyroid tissuesthyroid cancer

Eligibility Criteria

Age18 Years - 60 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64)
Sampling MethodProbability Sample
Study Population

all of this patients were recruited from the Affiliated Cancer Hospital of Xiangya Medical School

You may qualify if:

  • Clinical diagnosis of thyroid cancer Reciving thyroidectomy surgery No experience of radiation therapy Nice treatment compliance and follow-up regularly

You may not qualify if:

  • Prior history of malignancy ; Radiotherapy history, chemotherapy history; Serious concomitant diseases ; Chronic renal insufficiency and liver dysfunction

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

the Affiliated Cancer Hospital of Xiangya Medical School

Changsha, Hunan, 410078, China

Location

Biospecimen

Retention: SAMPLES WITHOUT DNA

Tissue samples were snap-frozen and stored in liquid nitrogen immediately after surgery.

MeSH Terms

Conditions

Thyroid Neoplasms

Interventions

Iodine-131

Condition Hierarchy (Ancestors)

Endocrine Gland NeoplasmsNeoplasms by SiteNeoplasmsHead and Neck NeoplasmsEndocrine System DiseasesThyroid Diseases

Study Officials

  • Zhi Li, Prof.

    Central South University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Xiangya Hospital, Central South University

Study Record Dates

First Submitted

January 16, 2018

First Posted

August 28, 2019

Study Start

January 16, 2016

Primary Completion

July 30, 2017

Study Completion

January 1, 2018

Last Updated

August 28, 2019

Record last verified: 2019-08

Data Sharing

IPD Sharing
Will not share

Locations

CN(1)